Investing.com -- 诺瓦瓦克斯医药( Novavax )(NASDAQ:NVAX)股价上涨5%,此前该公司宣布其H5N1禽流感疫苗候选产品的前临床结果积极,显示在非人类灵长类动物中产生了强烈的免疫反应。 这家生物技术公司的疫苗候选产品使用诺瓦瓦克斯医药的重组蛋白基纳米颗粒技术和Matrix-M佐剂,在单剂量或两剂量给药后,对当前流行的H5N1变种均显示出免疫原性。这项经同行评审的结果...
Source LinkInvesting.com -- 诺瓦瓦克斯医药( Novavax )(NASDAQ:NVAX)股价上涨5%,此前该公司宣布其H5N1禽流感疫苗候选产品的前临床结果积极,显示在非人类灵长类动物中产生了强烈的免疫反应。 这家生物技术公司的疫苗候选产品使用诺瓦瓦克斯医药的重组蛋白基纳米颗粒技术和Matrix-M佐剂,在单剂量或两剂量给药后,对当前流行的H5N1变种均显示出免疫原性。这项经同行评审的结果...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.